Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model

Life Sciences

Volumn 86, Issue 13-14, 2010, Pages 538-543

  Naito, Kiyohito ^a,b   Watari, Taiji ^a,b   Furuhata, Atsushi ^b   Yomogida, Shin ^b   Sakamoto, Koji ^c   Kurosawa, Hisashi ^d   Kaneko, Kazuo ^a   Nagaoka, Isao ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Koyo Chemical Co Ltd   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarkers; Glucosamine; Osteoarthritis; Type II collagen

Indexed keywords

COLLAGEN TYPE 2; GLUCOSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; ARTICULAR CARTILAGE; CHONDROPROTECTION; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; KNEE OSTEOARTHRITIS; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPRAGUE DAWLEY RAT; ANIMAL; BLOOD; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PATHOLOGY; STANDARD;

ANIMALIA; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; RATS; REFERENCE STANDARDS;

EID: 77950584640     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.02.015     Document Type: Article

References (34)

1. Aghazadeh-Habashi A., Sattari S., Pasutto F., Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. Journal of Pharmacy & Pharmaceutical Sciences 2002, 5(2):181-184.
2. Ameye L.G., Young M.F. Animal models of osteoarthritis: lessons learned while seeking the "Holy Grail". Current Opinion in Rheumatology 2006, 18(5):537-547.
3. Bendele A.M. Animal models of osteoarthritis. Journal of Musculoskeletal and Neuronal Interactions 2001, 1(4):363-376.
4. Bettica P., Cline G., Hart D.J., Meyer J., Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis & Rheumatism 2002, 46(12):3178-3184.
5. Buckwalter J.A., Mankin H.J. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instructional Course Lectures 1998, 47:487-504.
6. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham C.O., Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., Moreland L.W., Schumacher R., Oddis C.V., Wolfe F., Molitor J.A., Yocum D.E., Schnitzer T.J., Furst D.E., Sawitzke A.D., Shi H., Brandt K.D., Moskowitz R.W., Williams H.J. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine 2006, 354(8):795-808.
7. Crolle G., D'Este E. Glucosamine sulphate for the management of arthritis: a controlled clinical investigation. Current Medical Research and Opinion 1980, 7(2):104-109.
8. Derfoul A., Miyoshi A.D., Freeman D.E., Tuan R.S. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis and Cartilage 2007, 15(6):646-655.
9. Fenton J.I., Chlebek-Brown K.A., Peters T.L., Caron J.P., Orth M.W. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis and Cartilage 2000, 8(4):258-265.
10. Forchhammer L., Thorn M., Met O., Gad M., Weidner M.S., Claesson M.H. Immunobiological effects of glucosamine in vitro. Scandinavian Journal of Immunology 2003, 58(4):404-411.
11. Garnero P., Rousseau J.C., Delmas P.D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis & Rheumatism 2000, 43(5):953-968.
12. Garnero P., Piperno M., Gineyts E., Christgau S., Delmas P.D., Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Annals of the Rheumatic Diseases 2001, 60(6):619-626.
13. Gouze J.N., Bordji K., Gulberti S., Terlain B., Netter P., Magdalou J., Fournel-Gigleux S., Ouzzine M. Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β -mediated effects in rat chondrocytes. Arthritis & Rheumatism 2001, 44(2):351-360.
14. Hayami T., Pickarski M., Zhuo Y., Wesolowski G.A., Rodan G.A., Duong L.T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and minisectomized models of osteoarthritis. Bone 2006, 38(2):234-243.
15. Høegh-Andersen P., Tankó L.B., Andersen T.L., Lundberg C.V., Mo J.A., Heegaard A.M., Delaissé J.M., Christgau S. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Research & Therapy 2004, 6(2):R169-180.
16. Hua J., Sakamoto K., Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. Journal of Leukocyte Biology 2002, 71(4):632-640.
17. Hua J., Suguru S., Iwabuchi K., Tsutsumi-Ishii Y., Sakamoto K., Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide suppresses the ADP-mediated platelet activation in humans. Inflammation Research 2004, 53(12):680-688.
18. Hua J., Suguro S., Hirano S., Sakamoto K., Nagaoka I. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflammation Research 2005, 54(3):127-132.
19. Hua J., Sakamoto K., Kikukawa T., Abe C., Kurosawa H., Nagaoka I. Evaluation of the suppressive actions of glucosamine on the interleukin 1β-mediated activation of synoviocytes. Inflammation Research 2007, 56(10):432-438.
20. Jean Y.H., Wen Z.H., Chang Y.C., Lee H.S., Hsieh S.P., Wu C.T., Yeh C.C., Wong C.S. Hyaluronic acid attenuates osteoarthritis development in the anterior cruciate ligament-transected knee: association with excitatory amino acid release in the joint dialysate. Journal of Orthopaedic Research 2006, 24(5):1052-1061.
21. Lohmander L.S. What can we do about osteoarthritis?. Arthritis Research 2000, 2(2):95-100.
22. McAlindon T.E., Lavalley M.P., Gulin J.P., Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. Journal of the American Medical Association 2000, 283(11):1469-1475.
23. Nakamura H., Shibakawa A., Tanaka M., Kato T., Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clinical and Experimental Rheumatology 2004, 22(3):293-299.
24. Nakamura H., Masuko K., Yudoh K., Kato T., Kamada T., Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatology International 2007, 27(3):213-218.
25. Oegema T.R., Deloria L.B., Sandy J.D., Hart D.A. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis & Rheumatism 2002, 46(9):2495-2503.
26. Pavelká K., Gatterová J., Olejarová M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Archives of Internal Medicine 2002, 162(18):2113-2123.
27. Puhl W., Bernau A., Greiling H., Köpcke W., Pförringer W., Steck K.J., Zacher J., Scharf H.P. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis and Cartilage 1993, 1(4):233-241.
28. Radin E.L., Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clinical Orthopaedics and Related Research 1986, 213:34-40.
29. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J.E., Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. The Lancet 2001, 357(9252):251-256.
30. Rousseau J.C., Delmas P.D. Biological markers in osteoarthritis. Nature Clinical Practice Rheumatology 2007, 3(6):346-356.
31. Tang T., Muneta T., Ju Y.J., Nimura A., Miyazaki K., Masuda H., Mochizuki T., Sekiya I. Serum keratin sulfate transiently increases in the early stage of osteoarthritis during strenuous running of rats: protective effect of intraarticular hyaluronan injection. Arthritis Research & Therapy 2008, 10(1):R13.
32. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Robinson V., Hochberg M.C., Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews 2005, 18(2):CD002946.
33. van den Berg W.B. Lessons from animal models of osteoarthritis. Current Opinion in Rheumatology 2001, 13(5):452-456.
34. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zienstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008, 16(2):137-162.